In our ALL model utilizing CD19-BBζ CAR-T cells—both primary and iPSC-derived—we observed that the 1:1 CD4/CD8 mixed group exhibited intermediate antitumor efficacy: superior to CD8+ T cells alone but less effective than CD4+ T cells alone. Here, CD8A is linked to acute lymphoblastic leukemia.